The role of pro-drug therapy in the treatment of cancer

Drug Resistance Updates

Volumn 4, Issue 4, 2001, Pages 225-232

  Ferguson, Michelle J ^a   Ahmed, Fareeda Y ^a   Cassidy, Jim ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; DAUNORUBICIN; DNR GA3; DOX GA3; DOXORUBICIN; FLUOROURACIL DERIVATIVE; GLUCURONIDE; INTERLEUKIN 2 DERIVATIVE; MACROGOL DERIVATIVE; N (4 BETA GLUCURONYL 3 NITROBENZYLOXYCARBONYL)DOXORUBICIN; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PLATINUM; POLYGLUTAMIC ACID; POLYMER; PRODRUG; UFT; UNCLASSIFIED DRUG;

ALOPECIA; ANGIOGENESIS; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG CONJUGATION; DRUG EFFICACY; DRUG RESEARCH; HAND FOOT SYNDROME; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; SHORT SURVEY; SKIN TOXICITY; VOMITING;

EID: 0035736251     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0207     Document Type: Article

References (72)

1. Developments with targeted enzymes in cancer therapy
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
3. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study
4. Oral chemotherapy: Rational and future directions
5. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile
6. Multicenter phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer
7. Randomised comparitive study of ORZEL (oral uracil/Tegafur) plus leucovorin versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer
8. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues
9. Clinicopathological and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
10. Xeloda (capecitabine): An orally available tumour selective fluoropyrimidine carbamate
11. Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients
12. Cellular pharmacology of fluorinated pyrimidines in vivo in man
13. A Phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
14. A Phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
15. 1-Alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): Synthesis, physicochemical properties, and topical delivery of 5-FU
16. Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyl-5-FU prodrugs
17. In vivo evaluation of a novel antitumour prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5 fluorouracil upon hypoxic irradiation
18. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human cancer xenografts
19. A novel one-step tumor selective prodrug activation system
20. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody β-glucuronidase conjugate
21. Preclinical evaluation of the cardiac toxicity of HMR-1826, a prodrug of doxorubicin
22. The novel doxorubicin prodrug HMR-1826 inhibits human tumour growth in nude mice with minimal toxicity
23. The antitumour activity of the prodrug N-L-Leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts
24. The antitumour effects of the prodrug N-L-Leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts
25. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines
26. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-L-Leucyl-doxorubicin and its metabolites in a phase I clinical trial
27. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer
28. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer
29. Prostate specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
30. Prostate specific antigen forms complexes with human alpha2-macroglobulin and binds to the alpha2-macroglobulin receptor/LDL receptor related protein
31. PSA-specific and non PSA-specific conversion of a PSA targeted peptide conjugate of doxorubicin to its active metabolites
32. A peptide doxorubicin prodrug activated by prostate specific antigen selectively kills prostate tumor cells positive for prostate specific antigen in vivo
33. Chemistry and biology of taxol
34. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
35. Synthesis and biological evaluation of 2′-carbamate linked and 2′ carbonate linked prodrugs of paclitaxel: Selective activation by the tumor associated protease plasmin
36. Synthesis and evaluation of water soluble poly(ethylene glycol)-paclitaxel conjugate as a paclitaxel prodrug
37. Highly water soluble-taxol derivatives: 7-Poly(ethylene glycol) carbamates and carbonates
38. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): A water soluble prodrug
39. Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes
40. Structure and properties of pharmacologically active polymers
41. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanisms of tumoritropic accumulation of proteins and antitumor agent SMANCS
42. Use of oily contrast medium for selective targeting to tumor: Enhanced therapeutic effect and x-ray image
43. Liposomal formulations of anticancer drugs: Selectivity and effectiveness
44. Polyalkycyanoacrylate nanoparticles as drug carriers: Present state and prospectives
45. HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action
46. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model
47. Tumour tropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16/FI0 melanoma
48. Anticancer agents coupled to [N-(2-hydroxypropyl)methacrylamide] copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro
49. Degradation of side chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol proteinases
50. HPMA copolymers bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line
51. Phase I clinical and pharmacokinetic study of PK 1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates
52. Risk factors for doxorubicin-induced congestive heart failure
53. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor-pharmacokinetics in DBA2 mice
54. 1231-SPECT imaging and activity in hepatoma
55. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: Synthesis and preliminary in vitro and in vivo biological properties
56. HPMA copolymer platinates as novel antitumour agents: In vitro properties, pharmacokinetics and antitumour activity in vivo
57. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro
58. Phase I and pharmacological study of water soluble polymer-conjugated paclitaxel (PNU 166945) administered as a 1-hour infusion in patients with advanced solid tumors
59. Phase I pharmacokinetic (PK) study of MAG-CPT (PNU 166148), a polymeric derivative of camptothecin (CPT)
60. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
61. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose interleukin-2
62. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2
63. Synthesis and evaluation of water soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug
64. Camptothecin delivery systems: Enhanced efficacy and tumour accumulation of campothecin following its conjugation to polyethylene glycol via a glycine linker
65. A Phase I study of PEG-camptothecin (PEG-CPT) in patients with advanced solid tumours: A novel formulation for an insoluble but active agent
66. PEG prodrugs of cytosine arabinoside II: In vivo anti-tumour 1activity
67. L-asparaginase and PEG asparaginase - Past, present and future
68. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin
69. Complete regression of well established tumours using a novel water soluble poly(L-glutamic acid)-paclitaxel conjugate
70. Antitumour activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors